It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The risk of colorectal cancer (CRC) depends on environmental and genetic factors. Among environmental factors, an imbalance in the gut microbiota can increase CRC risk. Also, microbiota is influenced by host genetics. However, it is not known if germline variants influence CRC development by modulating microbiota composition. We investigated germline variants associated with the abundance of bacterial populations in the normal (non-involved) colorectal mucosa of 93 CRC patients and evaluated their possible role in disease. Using a multivariable linear regression, we assessed the association between germline variants identified by genome wide genotyping and bacteria abundances determined by 16S rRNA gene sequencing. We identified 37 germline variants associated with the abundance of the genera Bacteroides, Ruminococcus, Akkermansia, Faecalibacterium and Gemmiger and with alpha diversity. These variants are correlated with the expression of 58 genes involved in inflammatory responses, cell adhesion, apoptosis and barrier integrity. Genes and bacteria appear to be involved in the same processes. In fact, expression of the pro-inflammatory genes GAL, GSDMD and LY6H was correlated with the abundance of Bacteroides, which has pro-inflammatory properties; abundance of the anti-inflammatory genus Faecalibacterium correlated with expression of KAZN, with barrier-enhancing functions. Both the microbiota composition and local inflammation are regulated, at least partially, by the same germline variants. These variants may regulate the microenvironment in which bacteria grow and predispose to the development of cancer. Identification of these variants is the first step to identifying higher-risk individuals and proposing tailored preventive treatments that increase beneficial bacterial populations.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 National Research Council (ITB-CNR), Institute of Biomedical Technologies, Segrate, Italy (GRID:grid.5326.2) (ISNI:0000 0001 1940 4177)
2 Fondazione IRCCS Istituto Nazionale dei Tumori, Genetic Epidemiology and Pharmacogenomics Unit, Department of Research, Milan, Italy (GRID:grid.417893.0) (ISNI:0000 0001 0807 2568)
3 Fondazione IRCCS Istituto Nazionale dei Tumori, Genetic Epidemiology and Pharmacogenomics Unit, Department of Research, Milan, Italy (GRID:grid.417893.0) (ISNI:0000 0001 0807 2568); Azienda Ospedaliera Universitaria Integrata, UOC Laboratorio Analisi, Verona, Italy (GRID:grid.411475.2) (ISNI:0000 0004 1756 948X)
4 Valduce Hospital, Department of Surgery, Como, Italy (GRID:grid.417206.6) (ISNI:0000 0004 1757 9346)
5 Fondazione IRCCS Istituto Nazionale dei Tumori, Colorectal Surgery Unit, Milan, Italy (GRID:grid.417893.0) (ISNI:0000 0001 0807 2568)